Tenders Are Invited For Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accord ...

Work Detail

Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Buserelin, Atc L02ae01 For The Period January 1St, 2024 - December 31St, 2025. Section 130A Paragraph 8 Sgb V Enables Health Insurance Companies And Pharmaceutical Companies To Framework Discount Agreements For The Costs To Be Paid To The Statutory Health Insurance Companies Lock Medicines. With Regard To The Relevant Legal Regulations For The Awarding Of Public Contracts, There Is A Regular Process Of Active Ingredient-Related, Formal Procurement Procedures In Accordance With The Regulations Of Part 4 Of The Gwb By Dak-Gesundheit Instead Of. For Medicinal Products To Be Specified By The Bidder In Annex 2 To The Contract To The Above Active Ingredient, Buserelin, Atc L02ae01, Intends To Use Dak-Gesundheit Until On The Entry Into Force Of New Drug Discount Agreements With As Many Interested Parties As Possible To Conclude Drug Discount Agreements With Pharmaceutical Companies. A Discount Contract As A Rule, The Admission Model For The Above-Mentioned The Active Ingredient Comes Into Force For The First Time On January 1St, 2024 And Ends On December 31, 2025. Regardless, It Ends Automatically Upon Entry Into Force Exclusive Contract.

Contact Information

Other Detail